RCUS
Arcus Biosciences, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -6.2% ·
share flow +9.5% ·
net new positions -6.7%
· formula
Concentrated accumulation: rising shares among fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 84 | +2 | 62.09M | $1.91B | +9 | −7 |
| Q1 2026 | 85 | -2 | 57.45M | $1.24B | +6 | −8 |
| Q4 2025 | 87 | -1 | 64.26M | $1.53B | +1 | −2 |
| Q3 2025 | 20 | +2 | 36.84M | $500.99M | +2 | n/a |
| Q2 2025 | 15 | -1 | 35.18M | $286.34M | n/a | −1 |
| Q1 2025 | 13 | +2 | 11.54M | $90.60M | +4 | −2 |
| Q4 2024 | 11 | 0 | 8.18M | $121.86M | +1 | −1 |
| Q3 2024 | 10 | 0 | 4.70M | $71.80M | n/a | n/a |
| Q2 2024 | 10 | n/a | 4.00M | $60.94M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 11.46M | n/a | $93.27M | 0.0% | n/c | 1 | SEC ↗ ×15 |
| 2 | The Vanguard Group ✦ (passive) | 6.56M | n/a | $53.37M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 3 | Point72 Asset Management ✦ | 5.97M | +108.1% | $48.57M | 0.1% | ▲ Add | 5 | SEC ↗ |
| 4 | State Street Global Advisors ✦ (passive) | 3.63M | -1.8% | $29.55M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 5 | Fidelity (FMR) ✦ | 2.57M | n/a | $20.95M | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 6 | Geode Capital Management ✦ (passive) | 1.60M | +14.9% | $12.99M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 7 | Wellington Management ✦ | 936.02K | -13.6% | $7.62M | 0.0% | ▼ Trim | 2 | SEC ↗ ×4 |
| 8 | Millennium Management ✦ | 780.09K | -34.7% | $6.35M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 9 | Citadel Advisors ✦ | 611.20K | +62.1% | $4.98M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 10 | Two Sigma Investments ✦ | 408.19K | +36.8% | $3.32M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 11 | Renaissance Technologies ✦ | 368.10K | +80.4% | $3.00M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 12 | AQR Capital Management ✦ | 108.30K | +19.1% | $881,555 | 0.0% | ▲ Add | 5 | SEC ↗ ×4 |
| 13 | Fisher Asset Management ✦ | 88.16K | -36.0% | $717,646 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 14 | D. E. Shaw & Co. ✦ | 51.32K | -8.4% | $417,777 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 15 | T. Rowe Price ✦ | 44.37K | +30.2% | $362,000 | 0.0% | ▲ Add | 5 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Marshall Wace | $879,601 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 209 holders, 119.00M shares, $2.56B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 2.83K sh · $84,810
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology
24.7% of class · View original SEC filing ↗